2024-10-17 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Overview:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines.  

**Performance Comparison:**

* **Cumulative Return (PFE):** -11.2%
* **Cumulative Return (VOO):** 135.94%
* **Divergence:** -147.14 (Relative Divergence: 1.54)

PFE has significantly underperformed the S&P 500 (VOO) over the analyzed period, trailing by a substantial margin. The relative divergence of 1.54 indicates that PFE's performance has been significantly worse than the S&P 500 over the analyzed period, placing it at the lower end of its historical performance range.

**2. Recent Price Movements:**

* **Closing Price:** $29.44
* **5-Day Moving Average:** $29.45
* **20-Day Moving Average:** $29.17
* **60-Day Moving Average:** $29.26

PFE's stock price is currently trading slightly above its 5-day, 20-day, and 60-day moving averages, suggesting a slight upward trend. 

**3. Technical Indicators:**

* **RSI:** 55.73
* **PPO:** 0.13
* **Delta_Previous_Relative_Divergence:** -0.91 (Short-term downtrend)
* **Expected Return:** 0.0% (5-year expected return relative to VOO)

The RSI indicates that PFE is currently in neutral territory, neither overbought nor oversold. The PPO suggests a slight bullish momentum. The negative Delta_Previous_Relative_Divergence suggests a short-term downtrend. The expected return of 0.0% indicates that, based on historical trends, PFE is not expected to outperform the S&P 500 over the next five years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

PFE's most recent earnings report (2024-07-30) showed an EPS of $0.60, exceeding analysts' expectations of $0.458.  This positive earnings surprise may suggest potential growth opportunities.

**5. News and Recent Issues:**

**Recent Market Outlook:** 

**FINBOLD:**  Analysts remain optimistic about PFE's long-term prospects, citing its strong vaccine portfolio, innovative pipeline, and market leadership. However, some analysts express concerns about patent expirations and potential generic competition for key products.  

**Analyst Opinions and Performance Highlights:**

**Barron's:**  Analysts highlight PFE's strong financial performance and focus on developing new treatments for cancer, Alzheimer's disease, and other serious conditions. However, they also caution about potential regulatory hurdles and challenges in achieving sustained growth.

**6. Overall Analysis:**

PFE is a leading pharmaceutical company with a strong brand and a portfolio of key products. However, its recent performance has been underwhelming, significantly lagging the broader market.  While earnings have shown recent strength, concerns about patent expirations and competition could impact future growth.  Investors should carefully consider PFE's risk profile and potential long-term growth prospects before making any investment decisions. 

**7. Recommendations:**

While PFE's recent earnings beat may be positive, its overall performance has been disappointing, and its expected future returns are currently not exceeding the S&P 500.  For investors seeking higher returns, it might be prudent to explore other investment opportunities. 

**Disclaimer:**  This is not financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. 
